Omnipod 5 is the world’s first tubeless, wearable automated insulin delivery system that continuously adapts insulin delivery based on glucose levels and trends
ACTON, Mass.--(BUSINESS WIRE)--Mar. 16, 2021-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that the Company will host an investor webcast on Saturday, March 20, 2021 at 12:30 p.m. (Eastern time) focused on the Omnipod 5 pivotal trial data for adults and adolescents presented at ENDO 2021, a leading forum for worldwide endocrinology research and clinical care. The event will be hosted by Insulet and will include a presentation and an interactive question and answer session with the Company’s covering sell side analysts.
The link to the live call will be available on the Investor Relations section of the Company’s website at http://investors.insulet.com, “Events and Presentations,” and will be archived for future reference. Interested parties may also access the webcast here.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.omnipod.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316006005/en/
Deborah R. Gordon
Vice President, Investor Relations
Principal Investor Relations Analyst
Angela Geryak Wiczek
Senior Director, Corporate Communications
Source: Insulet Corporation